GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

GSK (NYSE:GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for patients with chronic obstructive pulmonary disease (COPD), a common lung ...

New study results with GSK's anti-IL-5 antibody Nucala in chronic obstructive pulmonary disease (COPD) have been published, just ahead of an FDA decision on the new indication scheduled for 7th May.

GSK has also filed Nucala with the FDA as a treatment for COPD. Analyst GlobalData forecasts that Nucala could be the leading anti-eosinophilic biologic therapy in 2025, with sales of $1.2 billion.

Nucala, which is administered as a once-monthly subcutaneous injection, won its first FDA approval in 2015 as a treatment for severe asthma. The Thursday approval came later than GSK expected.

While GSK’s Nucala may not have earned the distinction of becoming the first FDA approved biologic for chronic obstructive pulmonary disease (COPD), the British drugmaker is confident its IL-5 ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.

GSK said that if approved, Nucala could be the first biologic with monthly dosing for patients with COPD, which affects more than 390 million people globally and over 40 million people in Europe.

British drugmaker GSK said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive pulmonary disease (COPD), or smoker's lungs.